ASCO 2023 - good news for CHOSA

• Immuno Oncology with PD1 inhibitors successful in NSCLC in combination with cisplatin.
• CHOSA’s DRP has the potential to turn this combination into precision therapy.

CHOSA Oncology AB ("CHOSA") presents highlights from the American Society of Clinical Oncology (ASCO) in a video on the homepage.

Listen to CEO Peter Buhl Jensen’s presentation here

Previously communicated abstract on LiPlaCis data presented at ASCO can be found here .